All In Biotech

Drug Trial Radar · NCT03544905

Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33

A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.

Last checked: Nov 19, 2026Latest source record: Apr 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

206

Actual

Start

Jul 5, 2018

Primary completion

Dec 4, 2024

Study completion Dec 4, 2024

Sponsor

Lead sponsor
Haihe Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 4, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.

Conditions

  • Advanced Solid Tumors

Interventions

  • CYH33 for tabletDrug

    1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTD(Max tolerance does)Time frame: 35 days

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Lu'an People's Hospital

    Lu'an, Anhui, China

  • Lu'an Hospital of Traditional Chinese Medicine

    Lu'an, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Xiang'an Hospital of Xiamen University

    Xiamen, Fujian, China

  • Dongguan People's Hospital

    Dongguan, Guangdong, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Yuebei People's Hospital

    Shaoguan, Guangdong, China

  • Shenzhen Hospital of Cancer Hospital, Chinese Academy of Medical Sciences

    Shenzhen, Guangdong, China

  • Liuzhou Workers Hospital

    Liuzhou, Guangxi, China

  • Affiliated Tumor Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Anyang Cancer Hospital

    Anyang, Henan, China

  • Nanyang First People's Hospital

    Nanyang, Henan, China

  • The First Affiliated Hospital of Nanyang Medical College

    Nanyang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Hunan Province Directly Affiliated Traditional Chinese Medicine Hospital

    Zhuzhou, Hunan, China

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

  • Obstetrics and Gynecology Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital of Dali University

    Dali, Yunnan, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.